Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
0.565
-0.087 (-13.29%)
At close: Nov 20, 2024, 4:00 PM
0.567
+0.002 (0.43%)
Pre-market: Nov 21, 2024, 7:00 AM EST
Scilex Holding Company Employees
Scilex Holding Company had 105 employees as of December 31, 2023. The number of employees increased by 15 or 16.67% compared to the previous year.
Employees
105
Change (1Y)
15
Growth (1Y)
16.67%
Revenue / Employee
$484,124
Profits / Employee
-$1,633,648
Market Cap
74.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 105 | 15 | 16.67% |
| Dec 31, 2022 | 90 | 14 | 18.42% |
| Dec 31, 2021 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| 908 Devices | 230 |
| I-Mab | 220 |
| WORK Medical Technology Group LTD | 216 |
| CASI Pharmaceuticals | 176 |
| LENSAR | 130 |
| Armata Pharmaceuticals | 66 |
| Ikena Oncology | 43 |
| SELLAS Life Sciences Group | 16 |
SCLX News
- 14 days ago - Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali - GlobeNewsWire
- 22 days ago - Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms - GlobeNewsWire
- 23 days ago - Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock - GlobeNewsWire
- 24 days ago - Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - GlobeNewsWire
- 5 weeks ago - Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing - GlobeNewsWire
- 6 weeks ago - Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PRNewsWire